In a regulatory filing, BioAtla disclosed that its CEO Jay Short bought 50K shares of common stock on December 20th in a total transaction size of $107K. Shares of BioAtla are up 5% afterhours at $2.12.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCAB:
- BioAtla participates in a conference call with JPMorgan
- BioAtla to hold a virtual research and development day
- BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
- BioAtla hosting R&D Day to highlight BA3071 CAB-CTLA-4 Phase 1 data
- BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
